January 10, 2025 05:06 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
8 labourers still trapped in Assam's flooded mine even after 3 days of rescue ops | SC refuses to hear petitions seeking review of its same-sex marriage judgement, says there is 'no error' | 'They should wind up the alliance': Omar Abdullah on AAP-Congress fight over Delhi elections | Pune woman killed by her colleague in full public view for not paying back his money, no one intervenes | Los Angeles wildfire leaves 5 dead, forces 1 lakh including celebs to flee, Hollywood hills ablazed | PM Modi condoles death of six people in Tirupati stampede incident | Days after condemning Pak airstrikes, India in a first engages with Afghanistan's Taliban regime | 6 dead in stampede near Tirupati temple during token distribution to offer prayers | Prominent journalist-film producer Pritish Nandy dies of cardiac arrest at 73 | Thousands, including Hollywood stars, flee Los Angeles upscale neighbourhood as wildfire engulfs homes
DCGI approves Tata Group's low cost CRISPR Covid-19 test 'Feluda'

DCGI approves Tata Group's low cost CRISPR Covid-19 test 'Feluda'

Sep 21, 2020, at 07:55 am

Delhi/IBNS: The Drugs Controller General of India (DCGI) has given its approval for the commercial launch of India's first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Covid-19 test 'Feluda' developed by the Tata Group and CSIR-IGIB (Institute of Genomics and Integrative Biology).